Moreover, a study found that high SMARCA4 or SMARCA2 expression is frequently associated with opposite prognoses in BC (Guerrero-Martinez and Reyes, 2018), while high FOS expression has been associated with better BC prognosis (Fisler et al., 2018). Here, SMARCA4 is linked to breast cancer.